Programming - Hypertension Scientific Sessions
Hilton Chicago | Chicago, Illinois
Final Program
Hilton Chicago | Chicago, Illinois
Time | Event |
---|---|
1:00 p.m. to 5:00 p.m. | Satellite Event: National Heart, Lung, Blood Institute Hypertension T32 Trainee Session Salon A4 |
7:00 p.m. to 9:00 p.m. | Hypertension and KCVD Member Welcome Reception - NEW THIS YEAR! Salon A3 Tickets Required |
Time | Recent Advances/Basic/TAC Sessions | Clinical/Primary |
---|---|---|
7:30 a.m. to 9:00 a.m. |
Session 1 - Opening Remarks and Keynote Lecture 7:30 - Presidential Remarks 7:40 - Opening Remarks 7:50 - Welcome 8:00 - Opening Keynote Lecture Insights into Acute Kidney Injury and Transition to Chronic Kidney Disease Revealed by Multiomic and Spatial Technologies |
|
9:00 a.m. to 10:00 a.m. |
Session 2 - Keynote Lecture 9:10 - Immune Mechanisms of Hypertension |
|
10:00 a.m. to 10:30 a.m. | Break | |
10:30 a.m. to 12:00 p.m. |
Session 3 - Recent Advances Session (plenary) - New Drugs in the Treatment of Hypertension 10:30 - Mechanisms of Endothelin, ETA and ETB Receptors in Hypertension 11:00 - Endothelin Antagonists for Hypertension: Has Their Time Finally Arrived? 11:30 - The Potential Role of Aldosterone Synthase Inhibition to More Effectively Treat Hypertension |
|
12:00 p.m. to 1:00 p.m. |
Session 4 - Meet the Keynote Speakers Luncheon |
|
1:00 p.m. to 1:30 p.m. | Lunch on your own/Break | |
1:30 p.m. to 3:00 p.m. |
Session 5 - Recent Advances Session (plenary) The Evolving Story of APOL1-Mediated Kidney Disease: Transforming Understanding of Hypertension and Kidney Disease in those of African Ancestry 1:30 - Review of the Evolution of the Mechanistic Understanding of APOL1 High Risk Variants on Kidney Disease and Hypertension 2:00 - Understanding the Impact of APOL-1 Pore-Forming Function: From Epidemiology to In Vitro Studies 2:30 - A 14 Year Journey from Genetic Discovery to Rethinking Hypertensive Kidney Disease |
|
3:00 p.m. to 3:30 p.m. | Break | |
3:30 p.m. to 5:30 p.m. |
Session 6 - TAC Oral Abstract Sessions 3:30 - 01 Spatial Transcriptomics Reveals How Smooth Muscle Cells Transform to Renin-Expressing Cells During Homeostatic Challenge 3:45 - 02 Time restricted feeding reduces kidney fibrosis in diet-induced obesity through limiting kidney CD8+ T cell infiltration 4:00 - 03 Glomerular Hyperfiltration Promotes Chronic Kidney Disease through Interleukin 17A-Mediated Inflammation 4:15 - 04 Renal- and TAL-Specific Inhibition of Traf2 and NCK Interacting Kinase (TNIK) Decreases NKKC2 Phosphorylation and Blunts Salt-Sensitive Hypertension in Dahl Salt-Sensitive Rats
4:30 - 05 Renal Resident Tissue Macrophages Contribute to Salt-Dependent Increases in IL-6 4:45 - 06 Role of the Atrial Natriuretic Peptide in Mitochondria-mediated Proximal Tubule Epithelial Oxidative Stress in Type 1 Diabetic Kidney Disease 5:00 - 07 Ambulatory Blood Pressure Variability, Progression of Kidney Disease, and Cardiovascular Outcomes in the Chronic Renal Insufficiency Cohort 5:15 - 08 Genome-wide Maps of Human Kidney Proximal Tubules and Thick Ascending Limbs of Henle reveal an Enrichment for Human Blood Pressure associated Polymorphisms 4:30 – 5:30 3:30 - 09 Leucine Rich Repeat Containing 8A Anion Channels Modulate Vascular Reactivity in ApoE Knockout Mice 3:45 - 10 Adrenal Zona Glomerulosa Long Form Leptin Receptor (LepRb) Protects from Leptin-Mediated Vascular Disorders in Female Mice 4:00 - 11 The prostaglandin E2 receptor 4 in endothelial cells regulates the aorta integrity in hypertension mice model 4:15 - 12 Deficiency of Progranulin Decreases Mitochondrial Function and Induces a Whitening Phenotype in Perivascular Adipose Tissue, Suppressing Its Anti-Contractile Effects 4:30 - 13 Vascular Chemerin, Particularly from PVAT, contributes to Norepinephrine and Serotonin-Induced Vasoconstriction and Vascular Stiffness in a Sex-Dependent Manner 4:45 - 14 Arterial Stiffness in Obese Normotensive Children: The First Cardiovascular Risk Biomarker? 5:00 - 15 Cell-Free Mitochondrial DNA Drives Endothelial Cell Activation and Vascular Dysfunction via Toll-Like Receptor 9 and Inflammasome Pathway Activation 5:15 - 16 A Novel H2 Relaxin B-Chain-Only Peptide Variant B7-33 Improves The Pathophysiology Of Placental Ischemia In The Reduced Uterine Perfusion Pressure Rat Model Of Preeclampsia |
Session 6C - Clinical Practice/Clinical Science 3:30 to 4:30 3:30 - Who and when to screen? 3:45 - What testing should you perform? 4:00 - How to titrate treatment? 4:15 - Discussion/Q&A 4:30 to 5:306C2: Debate: Management of Resistant Hypertension- Drugs, Devices, or Lifestyle Salon A5 Moderators: Paul E Drawz and Anna Katherine Krawisz, MD 4:30 - Just give me a med! 4:42 - Just fix it with a catheter! 4:54 - Lifestyle is the way to go! 5:06 - Rebuttals 5:18 - Discussion/Q&A |
5:30 p.m. to 7:00 p.m. | POSTER SESSION 1: TAC Poster session/competition and reception Salon D |
Time | Recent Advances/Basic | Clinical/Primary |
---|---|---|
7:15 a.m. to 7:45 a.m. |
Astra Zeneca Industry Learning Studio |
|
7:00 a.m. to 7:45 a.m. |
Session 7 - American Heart Association Research: Grant Funding and Other Opportunities |
|
8:00 a.m. to 9:00 a.m. |
Session 8 -
Recent Advances Session (plenary) :
Mechanisms of Neurovascular Coupling and Hypertension 8:30 - Advanced Neuroimaging to Predict the Impact of Hypertension on Brain Health 9:00 - Hypertension and Brain Health: From Vascular Cognitive Impairment to Alzheimer’s Disease |
|
9:00 a.m. to 10:30 a.m. |
POSTER SESSION 2 |
|
10:30: a.m. to 12:00 p.m. |
Session 9 - Recent Advances Session (plenary): Hypertension without Borders 10:30 - Improving Hypertension Control in Populations With Health Disparities 11:00 - Closing the Gap: Practical Strategies for Global BP Control Equity 11:30 - Current Situation of Hypertension Incidence and Treatment in Japan |
|
12:00 p.m. to 1:30 p.m. | Lunch on your own/Exhibits | |
12:00 p.m. to 12:30 p.m. | Medtronic - Industry Sponsored Learning Studio Salon A3 |
|
12:00 p.m. to 1:30 p.m. | Session 10: Trainee Advocacy Committee CHAMP Lunch Salon A1 |
|
1:30 p.m. to 3:00 p.m. |
Session 11 - Recent Advances Session (plenary): Dietary Approaches to Hypertension 1:30 - Dissecting the Good and Bad Effects of Dietary Potassium on Blood Pressure 2:00 Leveraging the Microbiota as Medicine for Hypertension 2:30 - Dietary Approaches to Stop Hypertension (DASH): 1994-2024 |
|
3:00 p.m. to 3:30 p.m. | Break | |
3:30 p.m. to 5:00 p.m. |
Session 12 - Annual Hypertension Awards Session 3:30 - The Stephanie Watts Award Finalist Presentations 3:45 - British-Irish Hypertension Award 4:00 - Council on Hypertension Research Award cosponsored by Hypertension Australia
Effects of sodium ascorbate versus ascorbic acid in improving vasopressor response in sepsis 4:15 - New Investigator Award for Japanese Fellows: 4:30 - Harry Goldblatt Award for New Investigators: |
Session 12C - Clinical Practice/Clinical Science (CPCS) 3:30 - 4:30: 12C1 - What is CKM and PREVENT? 3:30 - Overview of AHA CKM 3:45 - PREVENT Risk Calculator 4:00 - Pros and Cons of PREVENT 4:15 - Discussion/Q&A 4:30 – 5:30 4:30 - Just give me the shot! 4:42 - Just give me the surgery! 4:54 - Just focus on your diet! 5:06 - Rebuttals 5:18 - Discussion/Q&A |
5:00 p.m. to 6:00 p.m. |
Oral Abstract Sessions 5:00 - 17 First-Line Beta Blocker Use Among >3.1 Million Veterans Initiating Hypertension Treatment, 2000-2022 12.B Influence of Hypertension on Cognition
5:00 - 21 The Detrimental Effects of a Comorbidity of Increased Blood Pressure Variability and High Salt Diet on Cardiovascular and Neurovascular Outcomes 5:15 - 22 Evaluation of the effects of CD8 knock-out on cognitive decline in the TAC-induced hypertension mouse model 5:30 - 23 Cognitive impairment during chronic i.c.v. angiotensin II is associated with increased tau phosphorylation in the cortex and hippocampus 5:45 - 24 Effects Of Intensive Blood Pressure Lowering on Brain Tissue Pulsatility in Hypertensive Patients
|
|
6:00 p.m. to 7:00 p.m. |
Session 13 |
|
7:30 p.m. to 10:30 p.m. | Trainee Advocacy Mixer Salon A1 |
Time | Recent Advances/Basic/TAC | Clinical/Primary |
---|---|---|
7:30 a.m. to 9:30 a.m. |
Session 14 7:30 to 8:00 - The Donald Seldin Lecture: 8:00 to 9:30 - Oral Abstract Sessions 8:00 - 25 The Blood Pressure Effects of a Just-in-time-adaptive Intervention for Physical Activity and Diet in Patients with Hypertension: A Randomized Controlled Trial 8:15 - 26 An Effective mHealth Intervention to Close the Guideline-to-Practice Gap in Hypertension Treatment: mGlide RCT 8:30 - 27 A Randomized Clinical Trial for Asymptomatic Elevated Blood Pressure in Patients Discharged from Emergency Department 14.B Oxidative Stress and Immune Mechanisms in Hypertension 8:00 - 31 Deacetylation Mimetic Mutation of Mitochondrial Superoxide Dismutase Attenuates Angiotensin II-Induced Hypertension by Protecting Against Oxidative Stress 8:15 - 32 Vγ6+ γδ T cells protect against angiotensin II-induced hypertension and vascular injury in male mice 8:30 - 33 CD4+ T Cell-Induced Renal Damage and Salt-Sensitive Hypertension is Not Modified by CD8+ T Cells 8:45 - 34 Elevation of Plasma anti-Endothelin A Receptor Autoantibodies in Lupus Subjects Correlates with Plasma Vascular Adhesion Molecule-1 Independent of Blood Pressure 9:00 - 35 The Dual Endothelin-1 Antagonist Aprocitentan Attenuates Mitochondrial Oxidative Stress in Human Cardiac Fibroblasts 9:15 - 36 Ablation of T-Lymphocyte β-Arrestins Reduces Inflammation and Increases Salt Retention in the Absence of Blood Pressure Changes Following Angiotensin II Infusion |
Session 14C - 7:30 to 8:30 - 7:30 - Case 1: Patient cannot tolerate any medications 7:45 - Case 2: Wide Pulse Pressure, SBP remains high, DBP low 8:00 - Case 3: Intermittent BP elevations / "spikes" 8:15 - Case 4: Severe autonomic dysfunction 8:30 to 9:30 8:30 - For which patients do we need more evidence? 8:45 - Do decentralized trials in hypertension make sense? 9:00 How should we measure BP in clinical trials? 9:15 - Discussion/Q&A |
9:30 a.m. to 10:00 a.m. | Break | |
10:00 a.m. to 12:00 p.m. |
Session 15 10:00 to 10:30 - Harriet Dustan Award: Enhanced Susceptibility of Females to a High-Fat Diet Continental Ballroom Jennifer C. Sullivan, PhD, FAHA
10:30 to 12:00 - 15.A Renal hemodynamics, tubular transport, salt and renovascular hypertension 10:30 - 37 Targeted Deletion of NKCC1 in Vascular Smooth Muscle Cells Lowers Blood Pressure in Normotensive and Hypertensive Mice 10:45 - 38 Loop Diuretic Resistance in a Preclinical Model of Cardiorenal Syndrome 2: Role of Enhanced Distal Convoluted Tubule Sodium Transport 11:00 - 39 Tryptophan contributes to the sex-dependent loss of diurnal sodium excretion in BMAL1 knockout rats. 11:15 - 40 Sodium-mediated Blood Pressure Increase in Chronic Kidney Disease and Diabetic Kidney Disease Patients Coincides With Vasodysfunction. 15.B Diabetes, Obesity and Microbiome15.B Diabetes, Obesity and Microbiome 10:30 - 41 SerpinA3N in Leptin Receptor Neurons Regulates Metabolic Homeostasis and Cardiovascular Function 10:45 - 42 Fecal Microbiota Transplantation Decreases Autoantibody Production and Lowers Blood Pressure in an Experimental Model of Autoimmune Disease 11:00 - 43 PAR1 Inhibition with Vorapaxar Enhances Renal Function and Modulates Inflammation Mediators in Diabetic Nephropathy 11:15 - 44 Transcutaneous hydrogen sulfide measurement as a way to evaluate skin blood flow |
Session 15C - Primary Care 10:00 to 11:00 10:00 - Classy treatment of hypertension: Everything you wanted to know about hypertension drug classes and side effects 10:15 - Tailoring therapy for distinct populations 10:30 - Combination therapy 10:45 - Discussion/Q&A 11:00 to 12:00 11:00 - Patient communication 11:15 - Social determinants of health 11:30 - Strategies for Developing and Implementing Treatment Plans from a Health Equity Lens |
12:00 p.m. to 12:30 p.m. |
Recor - Industry Sponsored Learning Studio |
|
12:30 p.m. to 1:30 p.m. |
Session 16 - Grantsmanship for Early Career Investigators NIH Grant Review Process Panelists: |
|
12:30 p.m. to 1:30 p.m. |
Session 17 |
|
1:30 p.m. to 3:00 p.m. |
18.A TAC Oral Abstract Award Competition 1:30 - 45 Deletion of a 4-bp noncoding genomic segment orthologous to human rs1882961 results in sex-divergent changes in salt-induced hypertension in Dahl salt-sensitive rats 1:45 - 46 Reduced Angiotensin II Type 2 Receptor-Mediated Responses Contribute to Increased Angiotensin II Vasoconstrictor Sensitivity in Otherwise Healthy Women With a History Of Preeclampsia 2:00 - 47 Deletion of PRR in AgRP Neurons of the Arcuate Nucleus Contributes to the Development of DOCA-Salt Hypertension 2:15 - 48 Cardiovascular Health Modifies Genetic Risk for the Hypertensive Disorders of Pregnancy 2:30 - 49 Activator protein 1 (AP-1) Complex in Antigen Presenting Cells contributes to Salt-Sensitive Blood Pressure in Humans 2:45- 50 The Comparison of Office Blood Pressure with Morning Home Blood Pressure: Self-Automated Measurement 18.B Too Much Potential: New Paradigms in Brain Mechanisms of Hypertension 1:30 - 51 Targeted Apoptosis of the Angiotensin AT1R-Expressing Subtype of Agouti-Related Peptide Neurons Increases Resting Metabolism and Blood Pressure 1:45 - 52 HIV-derived Proteins Induce Neuroinflammation, Hypertension, and Sympatho-activation via T cell-dependent mechanisms in the Tg26 Mouse Model 2:00 - 53 Chronic Angiotensin-(1-7) Treatment May Enhance GABAergic Neurotransmission onto Melanocortin-4 Receptor Neurons in The Hypothalamic Paraventricular Nucleus in a Sex-Specific Manner 2:15 - 54 The kidney-OVLT axis in renovascular hypertension: Individual and combined effects of afferent renal denervation and OVLT lesion in 2K1C rats. 2:30 - 55 Mouse Offspring Exposed to Preeclampsia/Eclampsia-like Symptoms Exhibit Changes in Regional Cerebral Perfusion at 2 months of age 2:45 - 56 High Blood Pressure Is Associated with Lower Brain Volume and Cortical Thickness in Healthy Young Adults
|
Session 18C -Hypertension Case Study Session
|
3:00 p.m to 3:30 p.m. | Break | |
3:30 p.m. to 5:30 p.m. |
Session 19 3:30 - KCVD Mid-Career Achievement Award: Hypertension in persons with kidney disease— different population, different disease. Meena S. Madhur, MD, PhD, FAHA 4:30 - 5:30 Oral Abstract Sessions 19.A Aldosterone 4:30 - 57 Macrolides for KCNJ5–mutated Aldosterone-Producing Adenoma (MAPA): a Study for Personalized Management of Primary Aldosteronism 4:45 - 58 The 5-HT7 receptor contributes to increased hindquarter blood flow caused by skeletal muscle contraction 5:00 - 59 Beclin-1-Dependent Autophagy Prevents Hyperaldosternism-Induced Endothelial Dysfunction And Hypertension 5:15 - 60 Atlas of Distal Nephron Mineralocorticoid Receptor-Dependent Transcriptome Reveals Novel Aldosterone Actions 19.B Pressure Sensing and Vascular Disease 4:30 - 61 Protective role of caspase-1 inhibition in experimental model of neonatal hyperoxia-induced cardiopulmonary dysfunction in adults born preterm. 4:45 - 62 Notch3 and the Vascular-Adipose Interactome in the Regulation of Adiponectin and Vascular Contraction 5:00 - 63 Acetylation of Mitochondrial Cyclophilin D Increases vascular Oxidative Stress, Induces Glycolitic Switch, Promotes Endothelial Dysfunction and Hypertension 5:15 - 64 Smooth Muscle Cullin-3 Regulates the Renal Baroreceptor Mechanism: a Link Between CUL3 and Integrin β1 |
Session 19C - Primary Care 3:30 to 4:30 - 19C1: Blood Pressure Measurement 3:30 - Standardization: Getting the most out of the office measurement 3:45 - Incorporating patient-measured blood pressure into clinical care: best practices/use cases 4:00 - Numbers you can use: devices and approaches 4:15 - Discussion/Q&A 4:30 to 5:30 - 19C2: Off the Cuff: "Podcast" Interview with the Experts |
5:45 p.m. to 6:15 p.m. |
Session 20 |
|
8:00 p.m. to 10:30 p.m. | Hypertension Awards Banquet Continental Ballroom (ticketed event) Includes Presentation of the: Fernando Elijovich Early Career Clinician Scientist Award Luke Joseph Laffin, MD |
Time | Recent Advances/Basic/TAC | Clinical/Primary |
---|---|---|
7:30 a.m. to 9:00 a.m. |
Session 21 - 7:30 - Sex Differences in Resilience to Hypertension 8:00 - New Concepts in Immune Mechanisms of Preeclampsia 8:30 - Renal Hemodynamics in Pregnancy |
|
9:00 a.m. to 9:30 a.m. | Break | |
9:30 a.m. to 11:00 a.m. | Session 22 Oral Abstract Sessions 22.A Preeclampsia and Developmental Programming 9:30 - 65 Postpartum Alterations of Middle Cerebral Artery Reactivity and Hemodynamics in a Transgenic Rat Model of Preeclampsia 9:45 - 66 Early-Life Sodium Restriction Programs Salt-Sensitivity of Autonomics and Blood Pressure in Adult C57BL/6J Mice 10:00 - 67 Cardiac Biomarkers in Pregnancies with and without Hypertension – a Case Control Study 10:15 - 68 Soluble FMS-Like Tyrosine Kinase 1 induces Vascular Endothelial Dysfunction in Pregnant Female Mice 10:30 - 69 Female Blood Pressure High 5 Mice Display Cerebral Hypoperfusion In the Non-Pregnant and Late Pregnant State 10:45 - 70 Cellular senescence as a driver of preeclampsia 22.B Genomic Influences on Blood Pressure 9:30 - 71 Analysis of First Morning Urine Transcriptomes in Normotensive and Hypertensive Patients Identify Upregulated Inflammatory and Signaling Pathways Associated with Hypertension 9:45 - 72 Genetic variance in heparan sulfation is associated with salt-sensitivity: a gene-environment analysis in EPIC-Norfolk, UK biobank, and HELIUS 10:00 - 73 Extracellular vesicles-derived miR-125b-5p/miR-125a-5p promotes hypertension by regulating angiotensin-converting enzyme 2 10:15 - 74 The rs1173771 Haplotype Associated with Blood Pressure Influences Chromatin Interactions Involving the Natriuretic Peptide Receptor 3 Gene Promoter 10:30 - 75 CTCF and Rad21 Mediated Regulation of Gene Expression in Human-Induced Pluripotent Stem Cells-derived Endothelial Cells 10:45 - 76 CASC15 lncRNA as a Mediator of Vascular Senescence in the Renin-Angiotensin System |
Session 22C 9:30 - 10:00 10:00 - 10:30 10:30 - 11:00 |
11:00 a. m. to 11:30 a.m. |
Session 23 - Kidney Metabolism and its Role in Hypertension |
|
11:30 a.m. |
Meeting Adjourns |
About This Meeting
Hypertension 2024 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.
This year's programming also includes:
- Recent Advances sessions
- Clinical Science/Clinical Practice Track
- Primary Care Track
- Oral abstract sessions highlighting early career oral abstract presentations
- Networking sessions
- Trainee Advocacy Committee Poster session and competition
- Award Lecture sessions
2024 Learning Objectives
- Discuss recent advances and emerging experimental models in hypertension.
- Summarize findings from recent clinical trials and the impact on future treatment and/or management of hypertensive disorders.
- Describe new therapeutic options for patients with hypertension.
- Describe best practices in the management of and scientific research in hypertensive disorders.
- Describe innovative approaches to conducting basic and/or clinical research.